Details for Patent: 5,508,297

Summary for Patent: 5,508,297

Title:	Vascular hypertrophy suppression treatment
Abstract:	This invention relates to a method for the prophylaxis or treatment of vascular hypertropy in a mammal by administering a pharmaceutically effective amount of a compound represented by the formula (I): wherein ring W is a nitrogen-containing heterocyclic ring residue which may be substituted; R1 is hydrogen or an optionally substituted hydrocarbon residue which optionally binds through a hetero-atom; R3 represents a group capable of forming an anion or a group capable of changing thereto; X shows that the phenylene and phenyl groups bind to each other directly or through a spacer having an atomic length of two or less; n denotes 1 or 2; a and b forming the heterocyclic ring residue are independently one or two optionally substituted carbon or hetero atoms; c is an optionally substituted carbon or hetero atom; provided that, when the ring W is a condensed ring, R1 is hydrogen or an optionally substituted hydrocarbon residue which binds through a hetero atom, or a salt thereof to a mammal in need thereof.
Inventor(s):	Kohei Nishikawa
Assignee:	Takeda Pharmaceutical Co Ltd
Application Number:	US08/201,122
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 5,508,297

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 5,508,297

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	5-036630	Feb 25, 1993

International Family Members for US Patent 5,508,297

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	218861
Canada	2115985
Germany	69430766